bioRxivCell Biology
Oncogenic Gata1 causes stage-specific megakaryocyte differentiation delay
G. Juban, N. Sakakini, H. Chagraoui, Q. Cheng, K. Soady, B. Stoilova, C. Garnett, D. Waithe, J. Doondeea, B. Usukhbayar, E. Karkoulia, M. Alexiou, J. Strouboulis, E. Morrissey, I. Roberts, C. Porcher, P. Vyas
Abstract
The megakaryocyte/erythroid Transient Myeloproliferative Disorder (TMD) in newborns with Down Syndrome (DS) occurs when N-terminal truncating mutations of the hemopoietic transcription factor GATA1, that produce GATA1short protein (GATA1s), are acquired early in development. Prior work has shown that murine GATA1s, by itself, causes a transient yolk sac myeloproliferative disorder. However, it is unclear where in the hemopoietic cellular hierarchy GATA1s exerts its effects to produce this myeloproliferative state. Here, through a detailed examination of hemopoiesis from murine GATA1s ES cells and GATA1s embryos we define defects in erythroid and megakaryocytic differentiation that occur relatively in hemopoiesis. GATA1s causes an arrest late in erythroid differentiation in vivo, and even more profoundly in ES-cell derived cultures, with a marked reduction of Ter-119 cells and reduced erythroid gene expression. In megakaryopoiesis, GATA1s causes a differentiation delay at a specific stage, with accumulation of immature, kit-expressing CD41hi megakaryocytic cells. In this specific megakaryocytic compartment, there are increased numbers of GATA1s cells in S-phase of cell cycle and reduced number of apoptotic cells compared to GATA1 cells in the same cell compartment. There is also a delay in maturation of these immature GATA1s megakaryocytic lineage cells compared to GATA1 cells at the same stage of differentiation. Finally, even when GATA1s megakaryocytic cells mature, they mature aberrantly with altered megakaryocyte-specific gene expression and activity of the mature megakaryocyte enzyme, acetylcholinesterase. These studies pinpoint the hemopoietic compartment where GATA1s megakaryocyte myeloproliferation occurs, defining where molecular studies should now be focussed to understand the oncogenic action of GATA1s.\n\nScientific CategoryHaematopoiesis and Stem Cells\n\nKey PointsGATA1s-induced stage-specific differentiation delay increases immature megakaryocytes in vivo and in vitro, during development.\n\nDifferentiation delay is associated with increased numbers of cells in S-phase and reduced apoptosis.
- organism: mouse
- assay: bulk RNA-seq
- research focus: cell type annotation
- research focus: differential expression
- research focus: cell signaling & trafficking
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Ontogeny drives stage-specific effects of a Gata1 mutation
Alina Sommer, Stephan Fischer, … Elisa Gomez Perdiguero·bioRxiv·Jan 15, 2025
- Single-cell transcriptomics reveal individual and synergistic effects of Trisomy 21 and GATA1s on hematopoiesis
Kaoru Takasaki, Eric K. Wafula, … Stella T. Chou·bioRxiv·May 24, 2024
- DLK1 is a GATA1s-Driven Dependency and Therapeutic Target in Down Syndrome-Associated Myeloid Leukemia
Lonneke Verboon, Sonali P. Barwe, … Anilkumar Gopalakrishnapillai·Blood AdvancesPeer-reviewed·Apr 7, 2026
- Stag2 dependent chromatin remodeling enforces the erythroid-specific Gata1 cistrome
Varun S. Sudunagunta, Edna M. Stewart, … Aaron D. Viny·BloodPeer-reviewed·May 18, 2026
- O-GlcNAc Homeostasis Controls Cell Fate Decisions During Hematopoiesis
Z. Zhang, M. P. Parker, … C. Slawson·bioRxiv·Jun 4, 2018
- Regulation of cell cycle by the novel GATA1/TAL1/Sphingomyelin Synthase 1 (SGMS1) transcriptional axis. Implications for anti-leukemic strategies.
Yasharah Raza, Sitapriya Moorthi, … Chiara Luberto·bioRxiv·Jan 19, 2025